$CMPS (COMPASS Pathways plc) COMPASS Pathways: Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression London, UK and New York, US, 19 January 2022 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health
Like CommentShare